CBAY - CymaBay Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.28
-0.47 (-6.96%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.75
Open6.69
Bid6.28 x 900
Ask6.29 x 800
Day's Range6.24 - 6.80
52 Week Range4.82 - 15.00
Volume1,425,267
Avg. Volume1,193,943
Market Cap431.411M
Beta (3Y Monthly)2.42
PE Ratio (TTM)N/A
EPS (TTM)-1.32
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.64
Trade prices are not sourced from all markets
  • CymaBay Therapeutics: What Investors Should Watch For
    Market Realistyesterday

    CymaBay Therapeutics: What Investors Should Watch For

    CymaBay Therapeutics (CBAY) is currently enrolling patients in its Phase 3 registrational trial, ENHANCE, to evaluate the use of its investigational PPARδ (peroxisome proliferator-activated receptor delta) agonist, seladelpar, in PBC (primary biliary cholangitis).

  • What’s Been Dragging Down CymaBay Therapeutics Stock
    Market Realistyesterday

    What’s Been Dragging Down CymaBay Therapeutics Stock

    CymaBay Therapeutics (CBAY) closed at $6.17 on June 12, 1.98% higher than its previous close, 28.01% above its 52-week low of $4.82, and 58.87% below its 52-week high of $15.

  • Intercept Pharmaceuticals, CymaBay’s and Viking’s Competitor
    Market Realistyesterday

    Intercept Pharmaceuticals, CymaBay’s and Viking’s Competitor

    Intercept Pharmaceuticals (ICPT) closed at $80.99 on June 12, 0.90% higher than its previous close, 10.93% above its 52-week low of $73.01, and 39.44% below its 52-week high of $133.74.

  • What Analysts Recommend for CBAY and VKTX
    Market Realistyesterday

    What Analysts Recommend for CBAY and VKTX

    This year, CymaBay Therapeutics (CBAY) has fallen 21.60% and Viking Therapeutics (VKTX) has risen 4.31%. While both clinical-stage companies focus on advancing their nonalcoholic steatohepatitis research and development programs, Viking seems to be ahead, considering its successful Phase 2 trials.

  • Hedge Funds Have Never Been This Bullish On CymaBay Therapeutics Inc (CBAY)
    Insider Monkey2 days ago

    Hedge Funds Have Never Been This Bullish On CymaBay Therapeutics Inc (CBAY)

    While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and optimism towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the first quarter and hedging or reducing many of their […]

  • CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
    Zacks3 days ago

    CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study

    CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.

  • Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
    Zacks3 days ago

    Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • Barrons.com3 days ago

    CymaBay Therapeutics Stock Plunged. Here’s Why It Could Be Time to Buy

    The small-cap biotech company released disappointing trial data on Tuesday, triggering a selloff. Raymond James analyst Steven Seedhouse says the stock is now a Strong Buy.

  • Benzinga3 days ago

    The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...

  • CymaBay Therapeutics Stock Crashes Over 50%: Is It Viable?
    Market Realist4 days ago

    CymaBay Therapeutics Stock Crashes Over 50%: Is It Viable?

    June 11 turned out to be a terrible day for US biopharmaceutical company CymaBay Therapeutics’ (CBAY) investors.

  • Here's Why CymaBay Therapeutics Collapsed Today
    Motley Fool4 days ago

    Here's Why CymaBay Therapeutics Collapsed Today

    The company reported disappointing interim data from an ongoing phase 2b trial in NASH, but it wasn't all bad news.

  • How Much Are CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Insiders Spending On Buying Shares?
    Simply Wall St.4 days ago

    How Much Are CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Insiders Spending On Buying Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • MarketWatch4 days ago

    CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors

    Shares of CymaBay Therapeutics Inc. plummeted 43% in premarket trade Tuesday after the biotech said data from an ongoing Phase 2 trial showed patients with nonalcoholic steatohepatitis (NASH) who were treated with investigational drug seladelpar did not show significant reductions in liver fat when compared with those on a placebo. However, treatment with seladelpar did result in a reduction in biomarkers associated with liver injury, the company said. "While the reductions in liver fat were minimal, we remain encouraged by the significant improvements in biochemical markers of liver injury that we observed at week 12," said Pol Boudes, CymaBay's chief medical officer. "The 52-week liver biopsy data will allow us to understand whether the improvement in liver injury markers will translate into histological improvement. The observed improvement in markers of liver injury are consistent with the observed effects of seladelpar in PBC and further support the potential for seladelpar to improve liver health." In NASH, fat builds up in the liver, triggering inflammation and cell injury that can lead to serious complications like cirrhosis, or liver scarring. There have been several trial updates in the NASH space so far this year from companies like Gilead Sciences Inc. and Intercept Pharmaceuticals Inc. , but they have not been promising, according to Jefferies health desk trader Jared Holz. "Investors have not been impressed with current data," he wrote in a note to clients Tuesday morning. Shares of CymaBay Therapeutics Inc. have gained 41% in the year to date through Monday, while the S&P 500 has gained 15%.

  • Benzinga4 days ago

    CymaBay Therapeutics Plummets 40% Following Liver Disease Data

    CymaBay Therapeutics (NASDAQCBAY) announced results from an ongoing 52-week Phase 2b dose-ranging, paired liver biopsy study of "seladelpar" for the treatment of nonalcoholic steatohepatitis. ...

  • GlobeNewswire4 days ago

    CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis

    -  Reductions in liver fat were minimal and not significant compared to placebo-  Reductions in markers of liver injury were robust and clinically meaningful-  Seladelpar.

  • Steven Cohen Takes an Interest in CymaBay Therapeutics
    GuruFocus.com5 days ago

    Steven Cohen Takes an Interest in CymaBay Therapeutics

    Guru invests in biopharmaceutical company focusing on liver disease

  • Options Traders Expect Huge Moves in CymaBay Therapeutics (CBAY) Stock
    Zacks24 days ago

    Options Traders Expect Huge Moves in CymaBay Therapeutics (CBAY) Stock

    CymaBay Therapeutics (CBAY) needs investors to pay close attention to the stock based on moves in the options market lately.

  • GlobeNewswire26 days ago

    CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DDW 2019

    Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in development for PBC and nonalcoholic steatohepatitis (NASH). A poster presentation titled “Capturing the experience and impact of itch in patients with primary biliary cholangitis (PBC),” highlighted results from a qualitative study designed to understand the experience and impact of itch on PBC patients and to examine the validity of three existing pruritus patient-reported outcome (PRO) measures (Itch Numeric Rating Scale (NRS), 5-D Itch Scale, and the Itch Visual Analogue Scale (VAS)).

  • Benzinga28 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

    Biotech stocks came under pressure this week along with the broader market, which succumbed to the negative sentiment generated by U.S.-China trade tensions. However, they recouped some of these losses, ...

  • Thomson Reuters StreetEvents29 days ago

    Edited Transcript of CBAY earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 Cymabay Therapeutics Inc Earnings Call

  • GlobeNewswirelast month

    CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update

    NEWARK, Calif., May 08, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.

  • GlobeNewswirelast month

    CymaBay Therapeutics Announces Multiple Presentations at DDW 2019

    CymaBay Therapeutics, Inc. (CBAY), today announced that multiple abstracts related to its seladelpar clinical development program for the treatment of primary biliary cholangitis (PBC) will be presented in poster sessions at Digestive Disease Week® (DDW) in San Diego, California from May 18 – 21, 2019. Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in development for PBC and nonalcoholic steatohepatitis (NASH). The presentations will include new data1 from a qualitative study in collaboration with the PBCers Organization, the Canadian PBC Society, and Evidera highlighting itch (pruritus) as a significant symptom for PBC patients with multiple impacts.

  • Genfit, Cymbay Hope to Crack Large Liver Disease Market
    GuruFocus.comlast month

    Genfit, Cymbay Hope to Crack Large Liver Disease Market

    Investors seeking to find the next great pharmaceutical company may want to concentrate on emerging biopharma. Warning! GuruFocus has detected 5 Warning Signs with GNFT. The company's focus is liver disease.

  • GlobeNewswire2 months ago

    CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8

    NEWARK, Calif., April 30, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.